Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc. has demonstrated significant clinical efficacy in its pipeline, particularly with icotrokinra, which shows progressive improvement in clinical response and endoscopic outcomes over time, indicating strong potential for successful treatment outcomes. The company's approach to targeting inflammatory diseases and leveraging its proprietary technology platform positions it strategically for growth, especially in the absence of effective competitors like Otezla. Furthermore, the strong business development track record of Protagonist and upcoming key catalysts projected for 2025 suggest a robust trajectory for the company, signaling a positive outlook on its future performance.

Bears say

Protagonist Therapeutics Inc faces significant challenges in its clinical development and competitive landscape, particularly with icotrokinra, despite its standout efficacy profile compared to existing oral treatment options for psoriasis. The company is exposed to various risks, including potential safety concerns from ongoing clinical trials, the possibility that strategic partners may withdraw from development due to competitive dynamics, and the implications of regulatory changes affecting pricing in the market. Additionally, concerns regarding future cash needs and the threat of dilution further contribute to a negative outlook on the stock.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.